Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.
Bevers LAH, Toledo G, Kisekka M, Kaudha E, Ahimbisibwe GM, Deprez I, Arumugan T, Variava E, Violari A, White I, Bbuye D, Nanduudu A, Mulwanyi E, Amuge P, Rutebarika DA, Kekitiinwa A, Kityo C, Musoke P, Archary M, Boles J, Thomason MJ, de Wildt SN, Giaquinto C, Colbers A, Burger DM, Buchanan AM, Chan MK, Jacobs TG, Turkova A; D3 TRIAL TEAM.
Bevers LAH, et al.
EBioMedicine. 2025 Oct;120:105929. doi: 10.1016/j.ebiom.2025.105929. Epub 2025 Sep 26.
EBioMedicine. 2025.
PMID: 41014973
Free PMC article.
Clinical Trial.